Literature DB >> 15780769

Overexpression of copper/zinc superoxide dismutase decreases ischemia-like astrocyte injury.

Jian Wang1, Joyce H Ma, Rona G Giffard.   

Abstract

Overexpression of copper/zinc superoxide dismutase (SOD1) in transgenic mice protects from transient focal cerebral ischemia in adult animals, but increases oxidative injury in perinatal mice. The effect of SOD1 overexpression on astrocytes subjected to ischemia-like insults has not yet been determined. Overexpression of human SOD1 in astrocytes resulted in a 3-fold increase in SOD1 activity without coupled up-regulation of catalase or glutathione peroxidase activities. Cells subjected to oxygen-glucose deprivation (OGD) or glucose deprivation to mimic ischemic injury were protected by SOD1 overexpression. OGD injury was reduced 47.6+/-9.3%, assessed by release of lactate dehydrogenase. OGD also caused a significant increase in catalase activity which was moderated by SOD1 overexpression. The level of glutathione in astrocytes overexpressing SOD1 was maintained at higher levels following 5 h OGD compared to control cultures under the same conditions. Reduction of glutathione prior to OGD significantly increased cell death of SOD1-overexpressing astrocytes as well as controls, but SOD1 still provided significant protection, suggesting that both GSH-dependent scavenging and GSH-independent scavenging are relevant to SOD1 protection in astrocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780769     DOI: 10.1016/j.freeradbiomed.2005.01.010

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  8 in total

1.  Astrocyte targeted overexpression of Hsp72 or SOD2 reduces neuronal vulnerability to forebrain ischemia.

Authors:  Lijun Xu; John F Emery; Yi-Bing Ouyang; Ludmila A Voloboueva; Rona G Giffard
Journal:  Glia       Date:  2010-07       Impact factor: 7.452

2.  Free radical scavenging activity and neuroprotective potentials of D138, one Cu(II)/Zn(II) Schiff-base complex derived from N,N'-bis(2-hydroxynaphthylmethylidene)-1,3-propanediamine.

Authors:  Che Wang; Zheng-Xu Cai; Zhong-Lu You; Hui-Shu Guo; De-Jing Shang; Xiao-Ling Wang; Liang Zhang; Li-Jie Ma; Jun Tan; Wei-Dong Le; Song Li
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

3.  Hyperoxia promotes astrocyte cell death after oxygen and glucose deprivation.

Authors:  Camelia A Danilov; Gary Fiskum
Journal:  Glia       Date:  2008-05       Impact factor: 7.452

Review 4.  SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments.

Authors:  Peter I Joyce; Pietro Fratta; Elizabeth M C Fisher; Abraham Acevedo-Arozena
Journal:  Mamm Genome       Date:  2011-06-26       Impact factor: 2.957

5.  Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector.

Authors:  Hugo Peluffo; Laia Acarin; Anna Arís; Pau González; Antoni Villaverde; Bernardo Castellano; Berta González
Journal:  BMC Neurosci       Date:  2006-04-25       Impact factor: 3.288

6.  Model systems of motor neuron diseases as a platform for studying pathogenic mechanisms and searching for therapeutic agents.

Authors:  K R Valetdinova; S P Medvedev; S M Zakian
Journal:  Acta Naturae       Date:  2015 Jan-Mar       Impact factor: 1.845

Review 7.  Glial Cells-The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment.

Authors:  Tereza Filipi; Zuzana Hermanova; Jana Tureckova; Ondrej Vanatko; And Miroslava Anderova
Journal:  J Clin Med       Date:  2020-01-18       Impact factor: 4.241

8.  The stimulatory effect of the octadecaneuropeptide ODN on astroglial antioxidant enzyme systems is mediated through a GPCR.

Authors:  Yosra Hamdi; Hadhemi Kaddour; David Vaudry; Salma Douiri; Seyma Bahdoudi; Jérôme Leprince; Hélène Castel; Hubert Vaudry; Mohamed Amri; Marie-Christine Tonon; Olfa Masmoudi-Kouki
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-21       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.